Project GIBS

Duration: 2012-2018
Global Influenza B Study

Nivel-logo-GIBS-250pxLinksBackground

GIBS was launched in 2012 and its aim is to collect information on the epidemiology and burden of disease of influenza B in the world during the past 10-15 years, in order to support prevention policies in the coming years. The GIBS is part of the Global Influenza Initiative (GII), an expert scientific forum that aims to address ongoing problems related to influenza worldwide.

Doel Research aims

The Global Influenza B Study (GIBS) was launched in 2012 and its aim is to collect information on the epidemiology and burden of disease of influenza B in the world during the past 10-15 years, in order to support prevention policies in the coming years.
The overall research question of GIBS is to assess differences in the epidemiology of influenza B and A worldwide, paying special attention to differences seen between countries in temperate regions compared to the tropics. Specific research questions include:

  • the global burden of influenza B (overall and compared to influenza A)
  • the frequency of influenza B vaccination mismatches
  • the spatiotemporal patterns of influenza B and A in temperate and tropical countries
  • the age distribution of influenza B and A.

Onderzoek (laten doen) met Nivel-bronnenSharing our research and results

We share our research and its results in providing access to the posters, oral presentations and scientific papers on the subject.

Publications
Poster presentations
  • 2020 | Poster: Measuring the burden of RSV among young children in primary care: Results of the RSV ComNet pilot in Italy and the Netherlands. Summeren JJGT van, Rizzo C, Hooiveld M, Korevaar J, Dückers M, Hendriksen J, Caini S, Bangert M, Demont C, Meijer A, Pandolfi E, Paget J. European Society for Paediatric Infectious Diseases (ESPID) virtual meeting, 26-29 October 2020.
  • 2017 | Poster: Significant changes in the timing of influenza epidemics in the WHO Euro region over the last 20 years: implications for national vaccination campaigns. Saverio Caini, François Schellevis, Clotilde El-Guerche Séblain, John Paget. Sixth ESWI influenza conference, Riga, Estonia, 10-13 September 2017.
  • 2017 | Poster: Epidemiology of seasonal influenza in the Middle East and North Africa, 2010-2016: circulating influenza A and B viruses and spatial spread of epidemics. Saverio Caini, Clotilde El-Guerche Séblain, Meral A Ciblak, John Paget. Sixth ESWI influenza conference, Riga, Estonia, 10-13 September 2017.
  • 2016 | Poster: Characteristics of seasonal influenza A and B in Latin America: influenza surveillance data from ten countries. Saverio Caini, Wladimir Alonso, Peter Spreeuwenberg, Clotilde El-Guerche Séblain, François Schellevis, John Paget, on behalf of the Global Influenza B Study. Options IX for the Control of Influenza, Chicago, USA, 24-28 August 2016.
  • 2016 | Poster: Is influenza B detected more frequently in children? Surveillance data from 30 countries around the world: findings from the Global Influenza B Study. Saverio Caini, Peter Spreeuwenberg, Clotilde El-Guerche Séblain, François Schellevis, John Paget, on behalf of the Global Influenza B Study. Options IX for the Control of Influenza, Chicago, USA, 24-28 August 2016.
  • 2016 | Poster: Age distribution of influenza patients infected with different influenza viruses: analysis of case-based surveillance data from 29 countries around the world. Caini S, Spreeuwenberg P, El-Guerche Séblain C, Schellevis F, Paget WJ, on behalf of the Global Influenza B Study. ISIRV Influenza 2016, Incidence, Severity and Impact of Influenza Conference. Paris, France, 21-22 January 2016.
  • 2015 | Poster: Temporal patterns of influenza A and B in the Northern hemisphere (including Europe) compared to the Southern hemisphere and the tropics: what are the lessons for influenza vaccination?. Saverio Caini, Schellevis F, Paget WJ, on behalf of the Global Influenza B Study. ESCAIDE 2015, Stockholm, Sweden, 11-13 November 2015.
  • 2014 | The epidemiological characteristics of influenza B compared to influenza A: results of the Global Influenza B Study. Caini S, Paget WJ. Huang QS, Ciblak MA, Schellevis F, Plotkin S, on behalf of the Global Influenza Initiative Study Group. Fifth ESWI influenza conference, Riga, Estonia, 12-15 September 2014.
  • 2013 | Poster: The global epidemiology of influenza B: disease burden and vaccine mismatches. Paget WJ, Caini S, Huang QS, Ciblak MA, Schoub BD, Plotkin S, on behalf of the Global Influenza Initiative. Options for the Control of Influenza VIII Conference, Cape Town, South Africa, 5-9 September 2013.
Oral presentations
  • 2020 | Disease burden of RSV in young children in primary care: RSV ComNet pilot study in Italy & the Netherlands. Summeren JJGT van, Rizzo C, Kwakkelstein S, Hooiveld M, Korevaar J, Dückers M, Hendriksen J, Caini S, Bangert M, Demont C, Meijer A, Pandolfi E, Paget J. European Scientific Working group on Influenza (ESWI) virtual meeting, 6-9 December 2020
  • 2016 | Can one define influenza transmission zones in Europe? The spatio-temporal characteristics of influenza A and B in the WHO Euro region. Saverio Caini, Wladimir J. Alonso, Clotilde El-Guerche Séblain, François Schellevis, John Paget, on behalf of the Global Influenza B Study. Options IX for the Control of Influenza, Chicago, USA, 24-28 August 2016 (rapid oral poster).


GereedschapMethodology

Over fifty countries in the Northern and Southern hemispheres and the inter-tropical belt were contacted and invited to join the GIBS study from June 2013 to February 2016. All countries were asked to make data available originating from their national influenza surveillance system during recent years (ideally from 2000-2013). In detail, each participating country was asked to provide the following:

  • Weekly number of influenza cases reported by the national surveillance system, broken down by age group and virus type (A, B), subtype (H3N2, seasonal H1N1, pandemic H1N1, H1N2, not subtyped) and lineage (Victoria, Yamagata, not characterized)
  • Weekly influenza-like illness (ILI)/acute respiratory infection (ARI) rates per 100 000 population or 100 consultations (depending on what is routinely available)
  • For countries that extend over large areas, especially when stretched across different climate zones, we asked for data stratified by region/province (if available).

All participating countries were also asked to complete a short questionnaire on the main features of their national influenza surveillance system, which included questions on: the ILI/ARI case definition in use, patients being sampled, representativeness of data, methods used for identification and characterization of influenza virus, and the population denominator.

ConsensusRationale

Seasonal influenza epidemics impose a heavy burden on society, with 3-5 million cases and 250,000 to 500,000 deaths worldwide every year. The resulting economic impact is large, and includes both direct and indirect costs. Traditionally, attention has been directed toward influenza A, which accounts for the majority of influenza cases in most seasons. During inter-pandemic periods, however, influenza B can represent a considerable proportion of total cases. Despite the important role of influenza B, we still have a relatively poor understanding of global epidemiology and burden of disease of influenza B. In particular, little is known on the epidemiology of influenza in the tropics, a region where approximately 40% of the world’s population live. Influenza activity in the tropics is quite different to other world regions: countries in these areas may experience two annual peaks, and epidemics are not as short and intense as in the Northern and Southern hemispheres. These differences can have important implications for effective and evidence-based decisions regarding the composition and period of administration of influenza vaccines.

WereldbolParticipating countries

As of December 2018, thirty-one countries around the world had joined the project by providing by providing influenza surveillance data: Argentina (province of Santa Fe), Australia, Bhutan, Brazil, Cameroon, Chile, China, Costa Rica, Ecuador, El Salvador, England, Guatemala, Honduras, Indonesia, Italy, Ivory Coast, Kazakhstan, Kenya, Madagascar, Morocco, the Netherlands, New Zealand, Nicaragua, Panama, Portugal, Singapore, South Africa, Turkey, Ukraine, United States, Vietnam.

GIBS Participating Countries

The GIBS database includes 1,850,358 cases of influenza, of which 23.0% are B. Information on age was available for 44% of cases in the database (dated 2018).

SamenwerkingsverbandInternational partners and interacting projects

The GIBS is a collaborative project that was made possible thanks to the cooperation and support of its partners:

Partners and external collaborations
  • Instituto Nacional de Enfermedades Respiratorias “Dr. Emilio Coni,” Santa Fe, Argentina.
  • Vaccine Preventable Diseases Surveillance Section, Health Policy Protection Branch, Office of Health Protection, Department of Health, Woden, Australia.
  • Public Health Laboratory, Department of Public Health, Ministry of Health, Thimphu, Bhutan.
  • Ministry of Health, Brasília, DF, Brazil.
  • Virology Department, Centre Pasteur du Cameroun, Yaounde, Cameroon.
  • Sección de Virus Respiratorios, Instituto de Salud Pública de Chile, Santiago de Chile, Chile.
  • Division of Infectious Disease, Key Laboratory of Surveillance and Early-warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing, China.
  • National Influenza Center, Ministry of Health, San José, Costa Rica.
  • Instituto Nacional de Investigacion en Salud Publica (INSPI), Centro de Referencia Nacional de Influenza y otros Virus Respiratorios, Guayaquil, Ecuador.
  • National Influenza Center, Ministry of Health, San Salvador, El Salvador.
  • Public Health England, Colindale, UK.
  • National Influenza Center, Ministry of Health, Guatemala City, Guatemala.
  • US Centers for Disease Control, Central American Region, Guatemala City, Guatemala.
  • National Influenza Center, Ministry of Health, Tegucigalpa, Honduras.
  • US Naval Medical Research Unit No. 2, Jakarta, Indonesia.
  • National Institute of Health, Rome, Italy.
  • Pasteur Institute of Côte d’Ivoire, Abidjan, Côte d’Ivoire.
  • National Institute of Public Hygiene, Abidjan, Côte d’Ivoire.
  • National Center of Expertise, Committee of Consumer Right Protection, Astana, Kazakhstan.
  • Centers for Disease Control and Prevention – Kenya Country Office, Nairobi, Kenya.
  • Institut Pasteur of Madagascar, Antananarivo, Madagascar.
  • National Influenza Center, Institut National d’Hygiène, Ministry of Health, Rabat, Morocco.
  • National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
  • Institute of Environmental Science and Research, Wellington, New Zealand.
  • National Influenza Center, Ministry of Health, Managua, Nicaragua.
  • National Influenza Center, IC Gorgas, Panama City, Panama.
  • National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal.
  • Ministry of Health, Singapore, Singapore.
  • Global Disease Detection, US-CDC, South Africa.
  • Zoonoses Research Center, Department of Medical Virology, University of Pretoria, Pretoria, South Africa.
  • Centre for Respiratory Diseases and Meningitis (CRDM), National Institute for Communicable Diseases, Johannesburg, South Africa.
  • School of Public Health, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa.
  • Istanbul University, Istanbul, Turkey.
  • L.V.Gromashevsky Institute of Epidemiology and Infectious Diseases National Academy of Medical Science of Ukraine, Kiev, Ukraine.
  • Epidemiology and Prevention Branch, Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • National Institute of Hygiene and Epidemiology, Hanoi, Vietnam.
GIBS also interacts with:
  • United States Centers for Disease Control and Prevention (US-CDC)
  • World Health Organization (WHO)
  • World Health Organization, Regional Office for Europe (WHO/Europe)
  • Global Influenza Initiative (GII)
  • Global Epidemiology Department, Sanofi Pasteur (Lyon, France)


Panels met patiënten, cliënten en burgersNivel project team

Participating Nivel researchers in GIBS are:

  • John Paget, PhD, senior researcher Nivel
  • Prof. Francois Schellevis MD PhD, senior researcher Nivel (retired)
  • Saverio Caini MD EPIET, guest researcher Nivel

SterFunding

The GIBS project has been supported by a number of research grants from Sanofi Pasteur. The current contract runs until October 2018 and is managed by the Global Epidemiology Department at Sanofi Pasteur.

Meer wetenMore information

For more information on this project you can contact one of the Nivel contacts on the right.
For more information about Nivel as a partner in healthcare services research, please feel free to contact our manager International Projects Inge van Houdt PhD.
We are looking forward tot get in touch with you.

 

Paget, J . Project GIBS. From: www.nivel.nl [Last update 14-April-2021; consulted on 16-April-2021]. URL: https://www.nivel.nl/en/international-projects/gibs